Back to Clinical Trials
Phase 3Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Sponsored by Eli Lilly and Company

About this study

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Where this study is enrolling (5)

  • Barbara Davis Center for Childhood Diabetes

    Aurora, Colorado

    Call 303-724-3861

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Tallahassee Memorial HealthCare

    Tallahassee, Florida

    Call 850-431-5404

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania

    Call 800-879-2467

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Driscoll Children's Hospital

    Corpus Christi, Texas

    Call 361-739-7250

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of Virginia

    Charlottesville, Virginia

    Call 434-422-2653

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
  • ✓Have at least one diabetes-related autoantibody found at screening
  • ✓Show signs of remaining beta-cell function
  • ✓stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening
  • ✓Weigh at least 8 kilograms (kg) (18 pounds) at screening

Exclusion criteria

  • ✕Have any other type of diabetes including gestational
  • ✕Have uncontrolled high blood pressure
  • ✕Have had a heart attack, heart disease, stroke, or heart failure
  • ✕Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
  • ✕Have a current or recent clinically serious medical condition or infection

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.